Lawrence Berkeley National Laboratory
Recent Work

Title
Mechanism of TRIM25 Catalytic Activation in the Antiviral RIG-I Pathway.

Permalink
https://escholarship.org/uc/item/8tj863hv

Journal
Cell reports, 16(5)

ISSN
2211-1247

Authors
Sanchez, Jacint G
Chiang, Jessica J
Sparrer, Konstantin Mj
et al.

Publication Date
2016-08-01

DOI
10.1016/j.celrep.2016.06.070

Peer reviewed
Mechanism of TRIM25 Catalytic Activation in the Antiviral RIG-I Pathway

Authors
Jacint G. Sanchez, Jessica J. Chiang, Konstantin M.J. Sparrer, ..., Banumathi Sankaran, Michaela U. Gack, Owen Pornillos

Correspondence
mgack@uchicago.edu (M.U.G.), opornillos@virginia.edu (O.P.)

In Brief
Sanchez et al. elucidate the structural requirements for TRIM25 catalytic activation and its effector functions in the antiviral RIG-I pathway. Higher-order oligomerization of TRIM25 is promoted by RIG-I and likely constitutes a regulatory mechanism of cellular antiviral response.

Highlights
● The TRIM25 RING domain dimerizes to make polyubiquitin chains and ubiquitinate RIG-I
● RING domain dimerization is facilitated by higher-order oligomerization of TRIM25
● Higher-order oligomerization of TRIM25 is facilitated by binding to RIG-I 2CARD
● Cooperative assembly of TRIM25 and RIG-I facilitates antiviral signaling

Accession Numbers
5EYA
Mechanism of TRIM25 Catalytic Activation in the Antiviral RIG-I Pathway

Jacint G. Sanchez,1 Jessica J. Chiang,2 Konstantin M.J. Sparrer,3 Steven L. Alam,4 Michael Chi,1 Marcin D. Roganowicz,1 Banumathi Sankaran,2 Michaela U. Gack,1,2,3,* and Owen Pornillos1,*

1Department of Molecular Physiology and Biological Physics, University of Virginia, Charlottesville, VA 22908, USA
2Department of Microbiology and Immunobiology, Harvard Medical School, Boston, MA 02115, USA
3Department of Microbiology, University of Chicago, Chicago, IL 60637, USA
4Department of Biochemistry, University of Utah, Salt Lake City, UT 84112, USA
5Molecular Biophysics and Integrated Bioimaging, Berkeley Center for Structural Biology, Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA
*Correspondence: mgack@uchicago.edu (M.U.G.), opornillos@virginia.edu (O.P.)

http://dx.doi.org/10.1016/j.celrep.2016.06.070

SUMMARY

Antiviral response pathways induce interferon by higher-order assembly of signaling complexes called signalosomes. Assembly of the RIG-I signalosome is regulated by K63-linked polyubiquitin chains, which are synthesized by the E3 ubiquitin ligase, TRIM25. We have previously shown that the TRIM25 coiled-coil domain is a stable, antiparallel dimer that positions two catalytic RING domains on opposite ends of an elongated rod. We now show that the RING domain is a separate self-association motif that engages ubiquitin-conjugated E2 enzymes as a dimer. RING dimerization is required for catalysis, TRIM25-mediated RIG-I ubiquitination, interferon induction, and antiviral activity. We also provide evidence that RING dimerization and E3 ligase activity are promoted by binding of the TRIM25 SPRY domain to the RIG-I effector domain. These results indicate that TRIM25 actively participates in higher-order assembly of the RIG-I signalosome and helps to fine-tune the efficiency of the RIG-I-mediated antiviral response.

INTRODUCTION

Higher-order assembly of large protein complexes is a recognized signal amplification mechanism that operates in many cellular signaling pathways (Wu, 2013). In the innate immune system, filamentous assemblies of the mitochondrial protein, MAVS (also known as CARDIF, VISA, or IPS-1), comprise one such type of signalosome (reviewed by Cai and Chen, 2014). MAVS filaments amplify signals from RIG-I-like pattern recognition receptors bound to viral RNA and recruit downstream effectors that ultimately generate a type I interferon (IFN) response. IFN-α/β gene expression induced by the RIG-I/MAVS signaling axis suppresses the replication of a variety of clinically important viral pathogens, including influenza A virus (IAV), hepatitis C virus, and dengue virus (reviewed by Goubau et al., 2013 and Loo and Gale, 2011).

Recent studies have shown that RIG-I-induced MAVS filament formation requires a remarkably simple biochemical trigger: interaction of the amino-terminal CARD (caspase activation and recruitment domain) of MAVS with a tetrameric assembly of the amino-terminal tandem CARDs (2CARD) of RNA-bound RIG-I (Jiang et al., 2012; Peisley et al., 2014; Wu et al., 2014). The RIG-I 2CARD tetramer is a helix with a single CARD as repeat unit, and so the 2CARD architecture restricts it to a “lock washer” configuration with only two helical turns (Peisley et al., 2014). The 2CARD “lock washer” acts as a template or seed for the single CARD of MAVS, which assembles along the helical trajectory to form long filaments containing several hundreds of MAVS CARD molecules (Peisley et al., 2014; Wu et al., 2014; Xu et al., 2014). MAVS filaments behave like prion fibers and thus are thought to commit the RIG-I pathway to an all-or-none or digital response to viral infection (Cai et al., 2014; Cai and Chen, 2014; Hou et al., 2011). Uncontrolled MAVS assembly will have harmful consequences to the cell, and so a number of mechanisms have evolved to regulate where, when, and how the RIG-I 2CARD seeds MAVS CARD assembly (reviewed by Chiang et al., 2014).

Ubiquitin (Ub) is a well-characterized regulator of the RIG-I 2CARD/MAVS CARD seeding mechanism (Gack et al., 2007, 2008; Jiang et al., 2012; Peisley et al., 2013, 2014; Zeng et al., 2010). Activated 2CARD is modified with K63-linked polyubiquitin chains (K63-polyUb) (Gack et al., 2007), and unanchored K63-polyUb chains were also shown to associate with RIG-I in biochemical reconstitution studies (Jiang et al., 2012; Zeng et al., 2010). Structural and biochemical studies have revealed that these K63-polyUb chains can wrap around four RIG-I 2CARD molecules to induce and stabilize the “lock washer” configuration (Jiang et al., 2012; Peisley et al., 2014). Both types of K63-polyUb chains are synthesized by the E3 ubiquitin ligase, TRIM25, which is an essential component of the RIG-I pathway (Gack et al., 2007; Zeng et al., 2010).

TRIM25 belongs to the tripartite motif (TRIM) protein family, which is characterized by a conserved domain organization at the N terminus (known as the TRIM or RBCC motif) composed of a catalytic RING domain, one or two B-box domains, and a
coiled-coil dimerization domain (Meroni and Diez-Roux, 2005; Figure 1A). In addition, TRIM25 has a C-terminal SPRY domain that binds to the RIG-I 2CARD (D'Cruz et al., 2013; Gack et al., 2007, 2008). TRIM proteins, like the well-characterized cullin ligases, are modular E3 enzymes. Similar to the cullin scaffold, the TRIM coiled-coil domain defines the spatial disposition of the catalytic RING domains.
the catalytic and substrate-binding/recruitment domains. The coiled-coil domain of TRIM25 makes an elongated, antiparallel dimer of hairpin-shaped subunits, which positions two RING domains on opposite ends of a 170-Å-long rod (Sanchez et al., 2014; Figure 1B). In the TRIM25 dimer, two C-terminal SPRY domains emanate from a four-helix bundle in the middle of the coiled coil. The SPRY domains are located on the same side of the dimer, which presumably allows them to simultaneously engage two substrate molecules (Goldstone et al., 2014; Li et al., 2014; Sanchez et al., 2014; Weinert et al., 2015). Cooperation between the catalytic and substrate-binding domains is likely facilitated by flexible linkers connecting these domains to the coiled-coil scaffold.

TRIM25 is recruited by RIG-I when RNA recognition by the helicase and C-terminal domains of RIG-I releases the 2CARD from autoinhibition (Jiang and Chen, 2011; Kowalinski et al., 2011; Luo et al., 2011), and the exposed 2CARD binds to the C-terminal SPRY domain of the E3 enzyme (D’Cruz et al., 2014; Sanchez et al., 2014; Weinert et al., 2015). Cooperation between the catalytic and substrate-binding domains is likely facilitated by flexible linkers connecting these domains to the coiled-coil scaffold.

TRIM25 catalytic activation. Here, we use structural, biochemical, and cell biological approaches to analyze the mechanism of catalytic activation of TRIM25. We found that the RING domain constitutes a self-association motif that dimerizes to make Ubc13C87K-Ub. The structure of the TRIM25 RING/Ubc13C87K-Ub complex was determined to 2.4-Å resolution (R/Re = 0.19/0.23).

Although the isolated TRIM25 RING domain is predominantly a monomer in solution (Figure S2A), it crystallized as a dimer in complex with Ubc13-Ub. This indicated that high-protein concentrations during crystallization and binding of Ubc13-Ub promoted dimerization of the RING domain. The TRIM25 RING/Ubc13-Ub complex is strikingly similar to the RING/E2-Ub complexes of RNF4 and BIRC7 (Dou et al., 2012; Plechanovova et al., 2012; Figures 2A and 2B). Each RING domain interacts with Ubc13-Ub through an extensive three-way interface. TRIM25 Arg54 coordinates an extensive hydrogen bond network that packs the Ub C-terminal tail against a shallow groove leading to the E2 active site (Figure 2C), and the zinc-bound His30 side chain makes a hydrogen bond with the Ub Glu32 carbonyl (Figure 2D). These interactions help hold Ub in the so-called “closed” conformation primed for catalysis (Dou et al., 2012; Plechanovova et al., 2012; Pruneda et al., 2012). Complex formation also induces allosteric remodeling of the E2 active site, with the Ubc13 Asn79 side chain amide making a hydrogen bond with the isopeptide (normally thioester) carbonyl and the Asp119 side chain positioned to activate the incoming lysine nucleophile (Figure 2C). Furthermore, the Ub moiety also makes hydrogen bonds with the second RING, involving RING side chains Glu22, Lys65, and Asn71; Ub backbone carbonyls; and the Ub Asp32 side chain positioned to activate the incoming lysine nucleophile (Figure 2C). The high-resolution structural details are very similar, and in many aspects identical, to the previously described RING/E2-Ub complexes of RNF4 (Plechanovova et al., 2012) and BIRC7 (Dou et al., 2012; Figures 2B–2D). The striking equivalence of the three structures strongly indicates that TRIM25 engages E2-Ub conjugates as a dimer.

RESULTS

Structure of the TRIM25 RING Domain in Complex with E2-Ub

The antiparallel architecture of the TRIM25 coiled-coil dimerization domain implies that the associated RING domains are separated by about 170 Å and so are effectively monomeric in this context (Figure 1B). Indeed, the TRIM25 RING was proposed to act as a monomer, similar to the CBL-B RING domain (Li et al., 2014). Nevertheless, many more RING domains engage E2 enzymes as dimers, as exemplified by the non-TRIM E3 ligases, RNF4 and BIRC7. Structures of these proteins, each bound to a covalent E2-Ub conjugate, have been demonstrated to represent the catalytically primed form of these enzymes (Dou et al., 2012; Plechanovova et al., 2012). We therefore reasoned that, if the TRIM25 RING domain catalyzes K63-polyUb synthesis as a dimer, then its crystal structure with the relevant E2-Ub should reveal an equivalent quaternary fold—including high-resolution details—as the RNF4 and BIRC7 complexes.

To facilitate structure determination, we first identified E2-conjugating enzymes suitable for such analysis. Two Ubc5 isoforms (Ubc5b and Ubc5c; also known as Ube2D2 and Ube2D3, respectively) and Ubc13 (also known as Ube2N) have been previously shown to function in the RIG-I pathway (Liu et al., 2013; Zeng et al., 2009, 2010). Accordingly, we found that the isolated RING domain of TRIM25 (residues 1–83) efficiently synthesized polyUb with these E2 enzymes (Figures 1C and S1); however, K63-polyUb chains were most efficiently made in vitro with Ubc13 and its partner, Uev1A (also known as Ube2V1; Figures 1D and 1E). Likewise, full-length TRIM25 is active with these E2 enzymes (Figure 1F). Interestingly, full-length TRIM25 predominantly made anchored Ub chains (auto-ubiquitination) with Ubc5b or Ubc13 alone and, conversely, only unanchored chains with Ubc13/Uev1A.

We were successful in co-crystallizing the TRIM25 RING domain with Ub-conjugated Ubc13 (Figure 2; Table S1). To prevent loss of the Ub moiety during crystallization, we used the previously described strategy of stably conjugating Ub to the E2 via an isopeptide linkage (Plechanovova et al., 2012) to make Ubc13C87K-Ub. The structure of the TRIM25 RING/Ubc13C87K-Ub complex was determined to 2.4-Å resolution (R/Re = 0.19/0.23).
Val72). The TRIM25 RING dimer is therefore reminiscent of the BRCA1/BARD1 heterodimer, in that helical elements outside the main zinc cores also mediate dimer formation (Brzovic et al., 2001). To validate the structure, we systematically substituted alanine for residues buried in both regions of the TRIM25 dimer interface and then purified the mutants (Figure 3B) and tested their catalytic activity (Figure 3C). Results showed that the RING mutants were invariably deficient in catalysis, with L69A and V72A showing the greatest deficiency (Figure 3C). Importantly, the size-exclusion profiles of all the RING mutants were similar to that of the wild-type protein, indicating that the mutants were also monomeric on purification and that none of the mutations affected the tertiary fold of the domain (Figure S3A). Similarly, the L69A and V72A mutations did not affect folding or the basal oligomerization of full-length TRIM25 (Figure S3B).

RING dimerization facilitates Ub conjugation because the two RING domains cooperate in holding the Ub moiety in a configuration primed for catalysis (Dou et al., 2012; Plechanovová et al., 2012). In contrast, the TRIM25 interface consists of a hydrogen bond network mediated in part by Lys65 and Asn71 (Figures 2D, top panel, and 4A). To confirm that this set of interactions is important for catalysis, we also generated the K65A, N71A, and N71D mutants (Figure 4B) and assayed them for ubiquitination activity (Figure 4C). Although the N71A mutant was still catalytically active, both the K65A and N71D mutants were severely deficient. Thus, like RNF4 and BIRC7, the second set of RING/Ub interactions is also required for TRIM25 catalytic activity.

In summary, the results of our structure-based mutagenesis experiments support the conclusion that the TRIM25 RING domain is catalytically active as a dimer. This has now been further confirmed by an independent structure of the TRIM25 RING domain in complex with Ubc5a-Ub, which was reported while this paper was under review (Koliopoulos et al., 2016). The TRIM5α RING domain in complex with unconjugated Ubc13 is also a dimer (Yudina et al., 2015), as are uncomplexed structures of TRIM37 (PDB 3LRQ) and TRIM32 (Koliopoulos et al., 2016), and so this may be a general property of the TRIM family of E3 ligases.

**TRIM25 RING Dimerization Is Required for RIG-I Signaling**

Our structural and biochemical analyses identified the RING domain as a second self-association motif in TRIM25, in addition
to the coiled-coil dimerization motif. We therefore sought to examine the requirement for both types of interactions in promoting RIG-I-mediated signaling. To test the signal-transducing activities of wild-type (WT) and mutant TRIM25 proteins without potentially confounding effects by the presence of endogenous TRIM25 protein, we utilized CRISPR technology to generate TRIM25-knockout (KO) HEK293T cells (Figure S4A; see Supplemental Experimental Procedures for details). Immunoblot (IB) analysis confirmed the absence of endogenous TRIM25 protein in these cells (Figure S4B). To further validate the TRIM25-KO cells, we tested them for their ability to support RIG-I 2CARD-mediated IFN-β promoter activation by a luciferase assay (Figure S4C). As previously shown (Gack et al., 2007), glutathione-S-transferase (GST)-fused RIG-I 2CARD (GST-2CARD) potently induced IFN-β promoter activation in normal (WT) HEK293T cells due to its constitutive signal-inducing activity. In contrast, IFN-β promoter activation induced by GST-2CARD was very low in TRIM25-KO cells (Figure S4C). Consistent with these results, an IAV infection assay showed low viral NS1 protein expression in WT cells, indicative of well-controlled virus replication (Figure S4D). In contrast, the expression of IAV NS1 protein was high in the TRIM25-KO cells, indicating that these cells are impaired in suppressing virus replication.

To determine the signal-promoting activity of TRIM25 mutants, we performed the IFN-β luciferase assay in TRIM25-KO cells that have been transfected with GST-2CARD together with two different amounts (1 or 5 ng) of plasmid encoding WT or mutant recombinant RING proteins. As previously shown (Gack et al., 2007), WT TRIM25 strongly enhanced GST-2CARD-mediated signaling in a dose-dependent manner (Figure 5A). In striking contrast, TRIM25 mutants harboring the L69A and V72A mutations, which disrupted the RING dimer interface, did not potentiate 2CARD-mediated signaling; that is, IFN-β promoter activation induced by GST-2CARD co-expressed with TRIM25 L69A or V72A was similar to that of GST-2CARD expressed alone. The lack of IFN-β-inducing activity of the TRIM25 L69A and V72A mutants correlated very well with loss of ubiquitination of the RIG-I 2CARD (Figure 5B), confirming that the abolished signal-promoting activity of TRIM25 L69A and V72A is due to defective E3 ligase activity.

We also tested TRIM25 proteins harboring Y245A and L252A mutations, which severely disrupted dimerization of the isolated coiled-coil domain (Sanchez et al., 2014). These TRIM25 mutants showed only slightly reduced activities in promoting GST-2CARD-mediated IFN-β promoter activation as compared to WT TRIM25 at higher expression, whereas they had similar activities to WT TRIM25 at low expression (Figure 5A). The TRIM25 coiled-coil mutants also supported GST-2CARD ubiquitination, although this was somewhat reduced compared to WT TRIM25, in particular for the L252A mutant (Figure 5B).

To determine the antiviral activity of TRIM25 mutants with disrupted RING dimer (L69A or V72A) or coiled-coil dimer (Y245A or L252A) interfaces, we reconstituted TRIM25-KO cells with the individual mutants and subsequently infected them with IAV. Cells transfected with empty vector or WT TRIM25 served as controls (Figures 5C and 5D). Cells reconstituted with WT TRIM25 potently inhibited viral titers (by more than four log) and viral NS1 protein expression as compared to cells reconstituted with empty vector (Vec). In contrast, cells reconstituted with the TRIM25 L69A or V72A mutant had similar viral titers and NS1 protein levels as vector-complemented cells, indicating a profound defect in antiviral activity of these TRIM25 mutants. Furthermore, cells reconstituted with the Y245A and L252A mutants showed only a slightly reduced antiviral activity as compared to WT TRIM25 (Figures 5C and 5D), which is consistent with the IFN-β luciferase and 2CARD ubiquitination data (Figures 5A and 5B).
Coiled-coil-mediated TRIM5β B-box domain, which facilitates spontaneous assembly of higher-order oligomerization and catalytic activation of TRIM25. Therefore, an appealing hypothesis is that TRIM25 and RIG-I mutually promote each other’s oligomerization and activation. Indeed, it has been demonstrated that K63-linked poly-Ub chains synthesized by TRIM25 can promote 2CARD tetramerization in vitro (Peisley et al., 2014). We therefore performed the complementary experiment to ask whether 2CARD promotes higher-order oligomerization and catalytic activation of TRIM25.

We first titrated TRIM25 concentrations in our ubiquitination reactions and found that, with 100 nM of full-length TRIM25, poly-Ub chain formation was minimal with either Ubc13/Uev1A (Figure 6A, lane 3) or Ubc5c (Figure 6A, lane 7). The same reactions were then performed in the presence of 1 μM of freshly purified His-tagged 2CARD, and we found that polyUb synthesis was very significantly enhanced (Figure 6A, compare lane 4 to lane 3 and lane 8 to lane 7). Thus, RIG-I 2CARD can promote TRIM25 RING/RING self-association in vitro and, by implication, higher-order oligomerization of coiled-coil-mediated TRIM25 dimers.

To determine whether polyUb-mediated 2CARD tetramerization was required for this effect, we measured catalysis using a Ub discharge assay in which polyUb chains were not being made (Middleton et al., 2014). In this assay, E2-Ub conjugates

![Figure 4. The Non-conserved Second Set of RING/Ub Interactions Is Required for Catalysis](image)

(A) Location of Asn71 and K65 (sticks) in context of the complex.
(B) Coomassie-stained SDS-PAGE gel of purified WT and mutant recombinant RING proteins. See also Figure S3.
(C and D) Ubiquitination assays with indicated RING mutants (5 μM) and Ubc13/Uev1A (250 nM). WT panels show corresponding control experiments, performed in parallel. Samples were analyzed by IB with anti-Ub.
were first synthesized by incubation of E1 and E2 enzymes with Ub and ATP. Discharge of the Ub moiety was then monitored by the disappearance of the E2-Ub conjugate and appearance of free E2, under conditions that prevent re-charging of the E2. To slow down the reaction, we used oxyester-linked Ubc5bS22R/C85S-Ub conjugates and did not add excess Ub acceptor amine (Middleton et al., 2014; Wright et al., 2016). In this assay format, we found that TRIM25 did not significantly increase the basal rate of free E2 accumulation, probably because dissociation of the RING/RING dimer or RING/E2-Ub complex was fast relative to oxyester cleavage. We then found that the presence of 2CARD also did not result in increased discharge (Figure 6B), even though we used a GST-2CARD fusion protein that was already dimeric due to the GST tag. On the other hand, when the added GST-2CARD was pre-incubated with K63-linked tetraUb, TRIM25-mediated discharge was increased. The effect was modest but was nevertheless evident, especially when comparing the initial time points (30–90 s), and was reproducibly observed in two independent experiments per- formed with independent protein preparations (Figure 6B). Because incubation with K63-linked polyUb chains induces 2CARD tetramerization in vitro (Peisley et al., 2014), these results indicated that the presence of the 2CARD tetramer also stabilized the TRIM25 RING dimer and/or RING/E2-Ub complexes, i.e., that 2CARD oligomerization and TRIM25 oligomerization can occur cooperatively.

Finally, we found that mutation of T55 in the first CARD, which is a critical residue for TRIM25 SPRY domain binding (Gack et al., 2008), did not increase TRIM25-mediated Ub discharge, even when the mutant GST-2CARD was pre-incubated with K63-linked polyUb (Figure 6B). This result confirmed expectation that RIG-I 2CARD-mediated TRIM25 activation is dependent on binding of 2CARD to the SPRY domain of TRIM25.
DISCUSSION

The essential role of TRIM25 in the RIG-I pathway is underscored by findings that viruses, such as IAV and dengue virus, have evolved mechanisms to suppress RIG-I signaling by specifically targeting and disrupting TRIM25 function (Gack et al., 2009; Manokaran et al., 2015; Rajsbaum et al., 2012). In this study, we confirm the essential requirement for TRIM25’s E3 ubiquitin ligase activity in RIG-I signaling (Gack et al., 2007) by showing that mutations that disrupt TRIM25 RING domain activation also reduce to background levels the ubiquitination of RIG-I 2CARD, 2CARD-dependent IFN induction, and antiviral activity against IAV. Furthermore, our results show that the TRIM25 RING domain must dimerize in order to productively engage Ub-conjugated E2 enzymes and become catalytically active, which is a common (but not universal) property of the RING family of E3 ubiquitin ligases (Lima and Schulman, 2012). Like other TRIM proteins, the basal oligomeric state of TRIM25 is a stable, coiled-coil-mediated dimer (Goldstone et al., 2014; Li et al., 2014; Sanchez et al., 2014; Weinert et al., 2015). The TRIM25 coiled-coil dimer has an antiparallel architecture, which places the two associated RING domains on opposite ends of an elongated rod (Sanchez et al., 2014). Therefore, TRIM25 RING dimers very likely form by means of higher-order oligomerization (or assembly) of the coiled-coil-mediated dimers.

We envision at least two possible types of assembled, catalytically active TRIM25: a tetramer form wherein one coiled-coil-mediated dimer would interact with a second to allow head-to-head interactions of their RING domains or a filamentous or net form wherein the RING domains on opposite ends of the coiled coil would interact with RING domains from separate dimers (Figure 7). TRIM5α, another well-characterized TRIM protein, makes higher-order complexes by the second mechanism; in this case, individual N-terminal RING domains are brought into close proximity by spontaneous trimerization of the downstream B-box 2 domains and assembly of TRIM5α dimers into an extended hexagonal network (Ganser-Pornillos et al., 2011; Li et al., 2016; Wagner et al., 2016; Yudina et al., 2015). Our analysis did not reveal a similar type of spontaneous high-order assembly behavior for TRIM25, indicating that its RING domains are brought into proximity by a different mechanism.

Initial recognition of viral RNA by RIG-I occurs at a tri- or di-phosphorylated blunt end of the viral RNA (Cui et al., 2008; Goubau et al., 2014; Hornung et al., 2006; Jiang and Chen, 2011; Kowalinski et al., 2011; Luo et al., 2011; Pichlmair et al., 2006). Multiple RIG-I molecules can decorate the same RNA (if it is of sufficient length) in an ATP-dependent manner (Peisley et al., 2013). This property of RIG-I is thought to promote clustering of activated 2CARDs, because a minimum of four 2CARD molecules is required to seed MAVS CARD filament assembly and initiate signaling (Peisley et al., 2013). Our findings that, at least in vitro, the isolated 2CARD can promote TRIM25 catalytic activation, in a manner that appears dependent on binding of 2CARD to the TRIM25 SPRY domain. These results indicate that RIG-I assembly on the viral RNA has the additional purpose of recruiting and clustering
Ubiquitin Discharge Assay

This assay was performed essentially as described (Wright et al., 2016). Ubc5bS22R/C85S-Ub oxyster-linked conjugate was prepared by mixing the following: 200 μM Ubc5b, 300 μM Ub, 1 μM E1, 50 mM Tris (pH 7.5), 150 mM NaCl, 5 mM ATP, 5 mM MgCl2, 0.5 mM TCEP, and 0.1% Triton X-100. After overnight incubation at 37°C, the E1 enzyme and free ATP were removed by gel filtration in 20 mM Tris (pH 7.5) and 150 mM NaCl. Fractions containing E2-Ub, free E2, and free Ub were collected and concentrated to 4 mg/ml (5× concentration). Discharge reactions containing 1× Ubc5bS22R/C85S-Ub, 1 μM TRIM25, and 8 μM GST-2CARD (WT or T55D), with or without 5 μM K63-linked tetraUb (Boston Biochem) in 50 mM Tris (pH 7.5) and 50 mM NaCl were incubated at 37°C. Time points were taken every 30 min over 3 hr and quenched by addition of non-reducing SDS-PAGE and subsequent placement on ice. Reactions products were visualized by SDS-PAGE and Coomasie staining. Free Ubc5bS22R/C85S was quantified by using a Li-COR Odyssey scanner. The experiment was performed twice, each with freshly purified batches of TRIM25 and 2CARD.

Structure Determination of the TRIM25 RING/Ubc13-Ub Complex

The purified RING and Ubc13C87K-Ub conjugate samples were diluted to 20 μM using their respective size exclusion buffers, mixed at equal volumes, and then concentrated to 10 mg/ml. Crystallization was performed in sitting drops with commercial screens at a 2:1 protein-to-precipitant ratio. Crystals formed in Hampton PEG/ion HT Screen condition no. D9 (0.2 M Li citrate and 20% polyethylene glycol (PEG) 3,350) after 2 days and were used for data collection without optimization. Ethylene glycol (10% [v/v] in mother liquor) was used as cryoprotectant. Diffraction data collected at beamline 6-3 of the Stanford Synchrotron Radiation Lightsource were indexed and scaled using HKL2000 (Otwinski and Minor, 1997).

The phase problem was solved by molecular replacement with crystal structures of human Ubc13 (PDB 1J7D) and Ub (PDB 1UBQ). The Ubc13 active site loop and Ub tail were removed from the search models to obtain unbiased densities for these regions. After positioning of the Ubc13 and Ub moieties, rigid body refinement also revealed strong densities for the zinc atoms in the RING domains as well as coordinating side chains and associated loops. These served as guides for calculation of 2-fold noncrystallographic symmetry (NCS) averaged maps, which were used to build the RING domains. Iterative refinement and manual model building were performed with PHENIX (version 1.9-1692; Adams et al., 2010) and Coot (Emsley et al., 2010). Secondary structure, torsion angle NCS, covalent bond and angle restraints for the Ubc13 K87-Ub G76 isopeptide, and zinc coordination (bond and angle) restraints were applied during refinement. Structure validation tools (as implemented in PHENIX and Coot) were used throughout the refinement process. Structure statistics are summarized in Table S1.

Cell Culture

Plasmodium and viruses, cell culture methods, and generation of TRIM25-KO Hek293T cells are described in Supplemental Experimental Methods.

IFN-β Luciferase Assay

TRIM25-KO Hek293T cells were seeded into 24-well plates. The next day, the cells were transfected with 100 ng of IFN-β luciferase reporter plasmid and 150 ng of β-galactosidase-expressing pGK-β-gal. To stimulate IFN-β promoter activity, cells were also transfected with 1 ng of plasmid encoding GST-2CARD together with 1 or 5 ng of empty pCMV vector or pCMV-FLAG-TRIM25 WT or mutant constructs. Twelve hours later, whole-cell lysates (WCLs) were prepared and subjected to a luciferase assay (Promega). Luciferase values were normalized to β-galactosidase activity to measure the transfection efficiency.
GST Pull-Down Assay and Immunoblot Analysis
Pelleted cells were lysed in NP-40 buffer (50 mM HEPES [pH 7.4], 150 mM NaCl, 1% [v/v] NP-40, and protease inhibitor cocktail [Roche]), followed by centrifugation at 13,000 rpm for 25 min. Lysates were mixed with a 50% slurry of glutathione-conjugated Sepharose beads (GE Healthcare), and the binding reaction was incubated for 3 hr at 4°C. Precipitates were washed extensively with lysis buffer. Proteins bound to the beads were separated by SDS-PAGE and transferred to a polyvinylidene difluoride (PVDF) membrane (Bio-Rad). Immunoblots were performed with anti-Ub (1:5,000; P4D1; Santa Cruz), anti-FLAG (1:2,000; Sigma), anti-gST (12,000; Sigma), anti-RIG-I (1:1,000; Adipogen), anti-TRIM25 (1:2,000; BD Biosciences), anti-actin (1:5,000–1:15,000; Sigma), or anti-NS1 (polyclonal rabbit; 1:3,000; kindly provided by Adolfo García-Sastre, Mount Sinai). The proteins were visualized by a chemiluminescence reagent (Pierce) and detected with a GE Healthcare Amersham Imager.

Influenza Replication Assays
TRIM25-KO HEK293T cells, seeded into 12-well plates, were transfected with 2 μg of pcMV empty vector or pcMV-FLAG-TRIM25 WT or mutant constructs. At 24 hr post-transfection, cells were infected with IAV (MOI 0.01) for 96 hr. To determine viral titers, supernatants were subjected to an endpoint titration (TCID50) assay on MDCK cells in DME supplemented with Pen-Strep, 0.2% BSA (Sigma), 25 mM HEPES, and 2 μg/ml TPK-trypsin ( Worthington Biochemicals), as described previously (Balish et al., 2013). Furthermore, cells were harvested and WCLs prepared and subjected to SDS-PAGE and IB analysis using anti-NS1, anti-FLAG, and anti-actin antibodies.

ACCESSION NUMBERS
The accession number for the structure factors and coordinates reported in this paper is PDB: SEYA.

SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures, five figures, and one table and can be found with this article online at https://dx.doi.org/10.1016/j.celrep.2016.06.070.

AUTHOR CONTRIBUTIONS
Conceptualization, Supervision, and Funding Acquisition, M.U.G. and O.P.; Methodology, J.G.S., J.J.C., K.M.J.S., S.L.A., M.C., M.D.R., and B.S.; Resources, B.S.; Writing – Original Draft, J.G.S., M.U.G., and O.P.; Writing – Review and Editing, J.G.S., M.D.R., M.U.G., and O.P.

ACKNOWLEDGMENTS
We thank Barbie Ganser-Pornillos for discussions and critical reading of the manuscript, Jonathan Wagner and Yueping Wan for technical support, and Adolfo García-Sastre for providing influenza PR8 virus. The Berkeley Center for Structural Biology is supported in part by the NIH, National Institute of General Medical Sciences, and the Howard Hughes Medical Institute. The Advanced Light Source is supported by the Director, Office of Science, Office of Basic Energy Sciences, of the US Department of Energy under contract no. DE-AC02-05CH11231. This study was supported by NIH grants R01-AI087846 (to M.U.G.) and R01-GM112506 (to O.P.). Seed funding was also provided by the Annette Lightner Foundation (to O.P.). J.G.S. was supported by a predoctoral Cell and Molecular Biology Training grant from NIH (T32-GM083183) and the Robert R. Wagner Fellowship Fund. K.M.J.S. was supported by a fellowship from the German Research Foundation (SP 1600/1-1). M.D.R. participated in this study while on leave from Łódz Technical University, Poland.

Received: December 17, 2015
Revised: May 11, 2016
Accepted: June 16, 2016
Published: July 14, 2016

REFERENCES
Adams, P.D., Afonine, P.V., Bunkóczi, G., Chen, V.B., Davis, I.W., Echols, N., Headd, J.J., Hurg, L.W., Kapral, G.J., Grosse-Kunstleve, R.W., et al. (2010). PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 66, 213–221.
Balish, A.L., Katz, J.M., and Klomv, A.I. (2013). Influenza: propagation, quantification, and storage. Curr. Protoc. Microbiol. 29, 15G.1.1–15G.1.24.
Brzovic, P.S., Rajagopali, P., Hoyt, D.W., King, M.C., and Klevit, R.E. (2001). Structure of a BRCA1-BARD1 heterodimeric RING-RING complex. Nat. Struct. Biol. 8, 833–837.
Cai, X., and Chen, Z.J. (2014). Prion-like polymerization as a signaling mechanism. Trends Immunol. 35, 622–630.
Cai, X., Chen, J., Xu, H., Liu, S., Jiang, Q.X., Halbmann, R., and Chen, Z.J. (2014). Prion-like polymerization underlies signal transduction in antiviral immune defense and inflammation. Cell 156, 1207–1222.
Chiang, J.J., Davis, M.E., and Gack, M.U. (2014). Regulation of RIG-I-like receptor signaling by host and viral proteins. Cytokine Growth Factor Rev. 25, 491–505.
Cui, S., Eisenhäuser, K., Kirchberger, A., Brzózka, K., Lammens, A., Lammens, K., Fujita, T., Conzelmann, K.K., Krug, A., and Hopfner, K.P. (2008). The C-terminal regulatory domain is the RNA 5′-triphosphate sensor of RIG-I. Mol. Cell 29, 169–179.
D’Cruz, A.A., Kershaw, N.J., Chiang, J.J., Wang, M.K., Nicola, N.A., Babon, J.J., Gack, M.U., and Nicholson, S.E. (2013). Crystal structure of the TRIM25 B30.2 (PRYSPRY) domain: a key component of antiviral signalling. Biochem. J. 456, 231–240.
Diaz-Griffero, F., Qin, X.R., Hayashi, F., Kigawa, T., Finzi, A., Sarnak, Z., Lienlauf, M., Yokoyama, S., and Sodroski, J. (2009). A B-box 2 surface patch important for TRIM5α self-association, capsid binding avidity, and retrovirus restriction. J. Virol. 83, 10737–10751.
Dou, H., Buetow, L., Sibbett, G.J., Cameron, K., and Huang, D.T. (2012). BIRC7-E2 ubiquitin conjugate structure reveals the mechanism of ubiquitin transfer by a RING dimer. Nat. Struct. Mol. Biol. 19, 876–883.
Emsley, P., Lohkamp, B., Scott, W.G., and Cowtan, K. (2010). Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486–501.
Gack, M.U., Shin, Y.C., Joo, C.H., Urano, T., Liang, C., Sun, L., Takeuchi, O., Akira, S., Chen, Z., Inoue, S., and Jung, J.U. (2007). TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-I-mediated antiviral activity. Nature 446, 916–920.
Gack, M.U., Kirchberger, A., Shin, Y.C., Inn, K.S., Liang, C., Cui, S., Myong, S., Ha, T., Hopfner, K.P., and Jung, J.U. (2008). Roles of RIG-I-N-terminal tandem CARD and splice variant in TRIM25-mediated antiviral signal transduction. Proc. Natl. Acad. Sci. USA 105, 16743–16748.
Gack, M.U., Albrecht, R.A., Urano, T., Inn, K.S., Huang, I.C., Carnero, E., Farzan, M., Inoue, S., Jung, J.U., and García-Sastre, A. (2009). Influenza A virus NS1 targets the ubiquitin ligase TRIM25 to evade recognition by the host viral RNA sensor RIG-I. Cell Host Microbe 5, 439–449.
Ganser-Pornillos, B.K., Chandrasekaran, V., Pornillos, O., Sodroski, J.G., Sundquist, W.I., and Yeager, M. (2011). Hexagonal assembly of a restricting TRIM5α protein. Proc. Natl. Acad. Sci. USA 108, 534–539.
Goldstone, D.C., Walker, P.A., Calder, L.J., Coombs, P.J., Kirpatrick, J., Ball, N.J., Hilditch, L., Yap, M.W., Rosenthal, P.B., Stoye, J.P., and Taylor, I.A. (2014). Structural studies of postentry restriction factors reveal antiparallel dimers that enable avid binding to the HIV-1 capsid lattice. Proc. Natl. Acad. Sci. USA 111, 9609–9614.
Goubau, D., Dedouche, S., and Reis e Sousa, C. (2013). Cytosolic sensing of viruses. Immunity 38, 855–869.
Goubau, D., Schlee, M., Dedouche, S., Prijssers, A.J., Zillinger, T., Golde, M., Schuberth, C., Van der Veer, A.G., Fujimura, T., Rehwinkel, J., et al. (2014). Antiviral immunity via RIG-I-mediated recognition of RNA bearing 5′-diphosphates. Nature 514, 372–375.
Hornung, V., Ellegast, J., Kim, S., Brzózka, K., Jung, A., Kato, H., Poeck, H., Akira, S., Conzelmann, K.K., Schlee, M., et al. (2006). 5′-Triphosphate RNA is the ligand for RIG-I. Science 314, 994–997.

Hou, F., Sun, L., Zheng, H., Skaug, B., Jiang, O.X., and Chen, Z.J. (2011). MAVS forms functional prion-like aggregates to activate and propagate antiviral innate immune response. Cell 146, 448–461.

Jiang, O.X., and Chen, Z.J. (2011). Structural insights into the activation of RIG-I, a nanosensor for viral RNAs. EMBO Rep. 13, 7–8.

Jiang, X., Kinch, L.N., Brautigam, C.A., Chen, X., Du, F., Grishin, N.V., and Chen, Z.J. (2012). Ubiquitin-induced oligomerization of the RNA sensors RIG-I and MDA5 activates antiviral innate immune response. Immunity 36, 959–973.

Koloppoulos, M.G., Esposito, D., Christodoulou, E., Taylor, I.A., and Rittinger, K. (2016). Functional role of TRIM E3 ligase oligomerization and regulation of catalytic activity. EMBO J. 35, 1204–1218.

Kovalinski, E., Lunardi, T., McCarthy, A.A., Louber, J., Brunel, J., Grigorov, B., Gerlier, D., and Cusack, S. (2011). Structural basis for the activation of innate immune pattern-recognition receptor RIG-I by viral RNA. Cell 147, 423–435.

Li, X., and Sodroski, J. (2008). The TRIM5a RIG-I, a nanosensor for viral RNAs. EMBO Rep. 13, 7–8.

Li, Y., Wu, H., Wu, W., Zhou, W., Liu, W., Zhang, Y., Cheng, M., Chen, Y.G., Gao, N., Yu, H., et al. (2014). Structural insights into the TRIM family of ubiquitin E3 ligases. Cell Res. 24, 762–765.

Li, Y.-L., Chandrasekaran, V., Carter, S.D., Woodward, C.L., Christensen, D.E., Dryden, K.A., Pornillos, O., Yeager, M., Ganser-Pornillos, B.K., Jensen, G.J., and Sundquist, W.I. (2016). Primate TRIM5 proteins form hexagonal nets on HIV-1 capsids. eLife 5, e16269.

Lima, C.D., and Schulman, B.A. (2012). Structural biology: a protein engagement RING. Nature 499, 43–44.

Liu, H.M., Loo, Y.M., Horn, S.M., Zornetzer, G.A., Katze, M.G., and Gale, M., Jr. (2012). The mitochondrial targeting chaperone 14-3-3zeta regulates a RIG-I translocon that mediates membrane association and innate antiviral immunity. Cell Host Microbe 11, 528–537.

Liu, S., Chen, J., Cai, X., Wu, J., Chen, X., Wu, Y.T., Sun, L., and Chen, Z.J. (2013). MAVS recruits multiple ubiquitin E3 ligases to activate antiviral signaling cascades. eLife 2, e00785.

Loo, Y.M., and Gale, M., Jr. (2011). Immune signaling by RIG-I-like receptors. Immunity 34, 680–692.

Luo, D., Ding, S.C., Vela, A., Kohlhaas, A., Lindenbach, B.D., and Pyle, A.M. (2011). Structural insights into RNA recognition by RIG-I. Cell 147, 409–422.

Manokaran, G., Finol, E., Wang, C., Gunaratne, J., Bahl, J., Ong, E.Z., Tan, C.P., Naślund, T.I., Liljestro¨ m, P., Weber, F., and Reis e Sousa, C. (2006). RIG-I-mediated antiviral responses to single-stranded RNA bearing 5′-phosphates. Science 314, 997–1001.

Pechanová, A., Jaffreg, E.Y., Tatham, M.H., Naismith, J.H., and Hay, R.T. (2012). Structure of a RING E3 ligase and ubiquitin-loaded E2 primed for catalysis. Nature 489, 115–120.

Pruneda, J.N., Littlefield, P.J., Soss, S.E., Nordquist, K.A., Chazin, W.J., Brzovic, P.S., and Klevit, R.E. (2012). Structure of an E3:E2–Ub complex reveals an allosteric mechanism shared among RING/U-box ligases. Mol. Cell 47, 933–942.

Rajbaum, R., Albrecht, R.A., Wang, M.K., Maharaj, N.P., Versteeg, G.A., Nis-tal-Villén, E., García-Sastre, A., and Gack, M.U. (2012). Species-specific inhibition of RIG-I ubiquitination and IFN induction by the influenza A virus NS1 protein. PLoS Pathog. 8, e1003059.

Sanchez, J.G., Okreglicka, K., Chandrasekaran, V., Welker, J.M., Sundquist, W.I., and Pornillos, O. (2014). The tripartite motif coiled-coil is an elongated antiparallel hairpin dimer. Proc. Natl. Acad. Sci. USA 111, 2494–2499.

Wagner, J.M., Raganowicz, M.D., Skorupka, K., Alam, S.L., Christensen, D.E., Doss, G.L., Wan, Y., Frank, G.A., Ganser-Pornillos, B.K., Sundquist, W.I., and Pornillos, O. (2016). Mechanism of B-box 2 domain-mediated higher-order assembly of the retroviral restriction factor TRIM5a. eLife 5, e16309.

Weinert, C., Morger, D., Djekic, A., Guttert, M.G., and Mittl, P.R. (2015). Crystal structure of TRIM20 C-terminal coiled-coil/B30.2 fragment: implications for the recognition of higher order oligomers. Sci. Rep. 5, 10819.

Wright, J.D., Mace, P.D., and Day, C.L. (2016). Secondary ubiquitin-RING docking enhances Arkadia and Ark2C E3 ligase activity. Nat Struct Mol Biol 23, 45–52.

Wu, H. (2013). Higher-order assemblies in a new paradigm of signal transduction. Cell 153, 287–292.

Wu, B., Peisley, A., Tetraut, D., Li, Z., Egelman, E.H., Magor, K.E., Walz, T., Penczek, P.A., andHur, S. (2014). Molecular imprinting as a signal-activation mechanism of the viral RNA sensor RIG-I. Mol. Cell 55, 511–523.

Xu, H., He, X., Zheng, H., Huang, L.J., Hou, F., Yu, Z., de la Cruz, M.J., Borkowski, B., Zhang, X., Chen, Z.J., and Jiang, X.Q. (2014). Structural basis for the antiparallel MAVS filaments in antiviral innate immunity. eLife 3, e10489.

Yudina, Z., Roa, A., Johnson, R., Biris, N., de Souza Aranha Vieira, D.A., Tsi-person, V., Reszka, N., Taylor, A.B., Hart, P.J., Demeler, B., et al. (2015). RING dimerization links higher-order assembly of TRIM5α to synthesis of K63-linked polyubiquitin. Cell Rep. 12, 788–797.

Zeng, W., Xu, M., Liu, S., Sun, L., and Chen, Z.J. (2009). Key role of Ubc6 and lysine-63 polyubiquitination in viral activation of IRF3. Mol. Cell 36, 315–325.

Zeng, W., Sun, L., Jiang, X., Chen, X., Hou, F., Adhikari, A., Xu, M., and Chen, Z.J. (2010). Reconstitution of the RIG-I pathway reveals a signaling role of unanchored polyubiquitin chains in innate immunity. Cell 141, 315–330.